You are here

Alnylam

Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?

Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?

Yahoo/Motley Fool

Flag link:

Alnylam kicks off #JPM18 with a restructured Sanofi deal, grabbing global rights to patisiran

Alnylam kicks off #JPM18 with a restructured Sanofi deal, grabbing global rights to patisiran

Endpoints

Flag link:

Alnylam, Sanofi given the all-clear to resume fitusiran trials

Alnylam, Sanofi given the all-clear to resume fitusiran trials

BioPharma Dive

clinical trials

Flag link:

8 Takeout targets to watch in 2018

8 Takeout targets to watch in 2018

BioPharma Dive

Bristol-Myers Squibb

Madrigal Pharmaceuticals

Spark Therapeutics

Flag link:

Four months after patient death, FDA’s hold lifted on Alnylam’s fitusiran

Four months after patient death, FDA’s hold lifted on Alnylam’s fitusiran

Endpoints

Flag link:

FDA adds ‘breakthrough’ status for Alnylam as patisiran starts its victory lap at the agency

FDA adds ‘breakthrough’ status for Alnylam as patisiran starts its victory lap at the agency

Endpoints

breakthrough status

Flag link:

Alnylam Starts Rolling NDA Submission for RNAi Candidate

Alnylam Starts Rolling NDA Submission for RNAi Candidate

Yahoo/Zacks.com

hereditary ATTR amyloidosis

Flag link:

Alnylam outshines Ionis with RNAi drug

Alnylam outshines Ionis with RNAi drug

BioPharma Dive

Ionis Pharmaceuticals

Flag link:

The Medicine Company's Dangerous Bet On Its LDL Cholesterol Lowering Drug

The Medicine Company's Dangerous Bet On Its LDL Cholesterol Lowering Drug

Forbes

The Medicine Company

LDL cholesterol

PCSK9 inhibitors

Flag link:

With $500M-plus, a buyout and two new billion-dollar pacts, upstart Vir is ready to roll on infectious diseases

With $500M-plus, a buyout and two new billion-dollar pacts, upstart Vir is ready to roll on infectious diseases

Endpoints

Vir Biotechnology

Flag link:

A drug 15 years in the making: Alnylam's quest to prove RNAi

A drug 15 years in the making: Alnylam's quest to prove RNAi

BioPharma Dive

Flag link:

3 Biotech Stocks That Skyrocketed Last Week: Can They Go Higher?

3 Biotech Stocks That Skyrocketed Last Week: Can They Go Higher?

Motley Fool

Madrigal Pharmaceuticals

Arbutus BioPharma

Flag link:

Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines

Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines

Stat

familial amyloid polyneuropathy

Flag link:

On Eve of Big Data Reveal, Patient Death Stalls Alnylam Hemophilia Drug

On Eve of Big Data Reveal, Patient Death Stalls Alnylam Hemophilia Drug

Xconomy

Flag link:

3 Biotech Stocks That Could Soar in September

3 Biotech Stocks That Could Soar in September

Motley Fool

PTC Therapeutics

Flag link:

Alnylam review turns up no clear answers on revusiran deaths

Alnylam review turns up no clear answers on revusiran deaths

BioPharma Dive

Flag link:

3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings

3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings

Yahoo/Zacks.com

Puma Biotechnology

Flag link:

Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug

Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug

Endpoints

clinical trials

Flag link:

5 Biotech Stocks With Major Catalysts in July

5 Biotech Stocks With Major Catalysts in July

Motley Fool

Puma Biotechnology

Flag link:

Alnylam lines up Phase 3 for another RNAi drug

Alnylam lines up Phase 3 for another RNAi drug

BioPharma Dive

acute hepatic porphyrias

Flag link:

Pages